Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 90 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Heavy Menstrual Bleeding Clear all
Recruiting Not applicable Interventional

Delivering tAN to Reduce HMB: The LUNA Study

NCT07326722
View directory record Official record
Conditions
Heavy Menstrual Bleeding
Interventions
Sparrow Link, Sparrow Link (Sham)
Device
Lead sponsor
Spark Biomedical, Inc.
Industry
Eligibility
14 Years to 45 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jul 22, 2026, 2:26 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Study of Conventional Laparoscopic Hysterectomy Versus Robot-Assisted Laparoscopic Hysterectomy at a Teaching Institution

NCT01581905
View directory record Official record
Conditions
Menorrhagia, Dysfunctional Uterine Bleeding, Leiomyoma, Pelvic Pain, Endometriosis
Interventions
Conventional Laparoscopic Hysterectomy (LH), Robot Assisted Hysterectomy
Procedure
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

NCT03271489
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Uterine Fibroids
Interventions
Elagolix, Estradiol /norethindrone acetate (E2/NETA), E2/NETA Placebo, Elagolix Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
155
States / cities
Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 112 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2025 · Synced Jul 22, 2026, 2:26 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

HMB- Data Collection Methods

NCT02001324
View directory record Official record
Conditions
Heavy Menstrual Bleeding
Interventions
Web-based data collection, Paper-based data collection
Other
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years to 51 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Not applicable Interventional Results available

Tranexamic Acid (TA) vs Combined Oral Contraceptive (COCP) Pilot Study

NCT01428713
View directory record Official record
Conditions
Menorrhagia
Interventions
Oral tranexamic acid, Oral Contraceptive Pills
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 21 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Early Phase 1 Interventional

Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers

NCT03272568
View directory record Official record
Conditions
Hemophilia, Menstrual Flow Excessive
Interventions
Recombinant FVIII Fc fusion product Eloctate, Recombinant FIX Fc fusion product Alprolix, Patient-operated diagnostic device for anemia AnemoCheck.
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
14 Years to 55 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 17, 2020 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study Comparing Conventional vs. Robotic-assisted Laparoscopic Hysterectomy

NCT00485355
View directory record Official record
Conditions
Uterine Fibroids, Menorrhagia, Endometriosis
Interventions
conventional laparoscopic hysterectomy, robotic assisted laparoscopic hysterectomy
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 18, 2014 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Not applicable Interventional

Treatment and Management of Women With Bleeding Disorders

NCT00111215
View directory record Official record
Conditions
Menorrhagia, Blood Coagulation Disorders, Blood Platelet Disorders, Von Willebrand Disease, Hematologic Disease
Interventions
Tranexamic Acid, Desmopressin Acetate
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
6
States / cities
Atlanta, Georgia • East Lansing, Michigan • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2007 · Synced Jul 22, 2026, 2:26 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Treatment of Menorrhagia in Women With Thrombocytopenia Using Platelets or Platelets and Hormones

NCT00556400
View directory record Official record
Conditions
Aplastic Anemia, Menorrhagia, Amenorrhea
Interventions
Lo-Ovral Oral Contraceptive Pills, Placebo - sugar pill
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
12 Years to 55 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Not applicable Interventional

Sleep and Health Outcomes in Women With Heavy Menses

NCT05722444
View directory record Official record
Conditions
Menstruation; Heavy
Interventions
Nighttime Feminine Product
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effectiveness of Truclear on Patient Quality of Life

NCT02934789
View directory record Official record
Conditions
Heavy Menstrual Bleeding
Interventions
Hysteroscopic myomectomy with Truclear, Medical therapy
Procedure · Drug
Lead sponsor
All For Women Healthcare, Illinois
Other
Eligibility
21 Years to 80 Years · Female only
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

NCT03886220
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Elagolix, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
45
States / cities
Birmingham, Alabama • Searcy, Arkansas • La Mesa, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 3 Interventional Results available

Safety Study of XP12B in Women With Menorrhagia

NCT00113568
View directory record Official record
Conditions
Menorrhagia, Heavy Menstrual Bleeding
Interventions
Tranexamic acid tablets (XP12B)
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
784 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
59
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2010 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Modified Treatment Regimens for Treatment of Heavy Menstrual Bleeding Using the HerOption® System

NCT00094536
View directory record Official record
Conditions
Menorrhagia
Interventions
Extended treatment regimen using Her Option Cryotherapy
Device
Lead sponsor
CooperSurgical Inc.
Industry
Eligibility
30 Years to 100 Years · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
7
States / cities
Phoenix, Arizona • Wellington, Florida • Burlington, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Not applicable Interventional

Ultrasound Evaluation Versus Direct Measurement of Uterine Cavity Length

NCT04425577
View directory record Official record
Conditions
Dysmenorrhea, Heavy Menstrual Bleeding, Contraception
Interventions
Transabdominal Ultrasound
Diagnostic Test
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
12 Years to 22 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Not applicable Interventional

Transcutaneous Auricular Neurostimulation as a Treatment for Women With Heavy Menstrual Bleeding: A Dose-finding Trial

NCT06814028
View directory record Official record
Conditions
Heavy Menstrual Bleeding
Interventions
Volta System
Device
Lead sponsor
Spark Biomedical, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of XP12B in Women With Menorrhagia

NCT00401193
View directory record Official record
Conditions
Menorrhagia, Heavy Menstrual Bleeding
Interventions
Tranexamic acid tablets, Placebo tablets
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
83
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Jul 22, 2026, 2:26 PM EDT
Recruiting Phase 3 Interventional

A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

NCT05862272
View directory record Official record
Conditions
Uterine Fibroids, Endometriosis
Interventions
Relugolix Combination Tablet
Drug
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
120
States / cities
Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)

NCT02691494
View directory record Official record
Conditions
Uterine Fibroids, Heavy Menstrual Bleeding
Interventions
Elagolix, Placebo for Estradiol/Norethindrone Acetate, Estradiol/Norethindrone Acetate, Placebo for Elagolix
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
103
States / cities
Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 89 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Not applicable Interventional Results available

A CLinical Study to Evaluate the Safety And Effectiveness of the CeRene DevIce to Treat HeavY Menstrual Bleeding

NCT02842736
View directory record Official record
Conditions
Menorrhagia
Interventions
Cerene(R) Cryotherapy Device
Device
Lead sponsor
Channel Medsystems
Industry
Eligibility
25 Years to 50 Years · Female only
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
9
States / cities
Arlington Heights, Illinois • Naperville, Illinois • Fort Wayne, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

NCT02654054
View directory record Official record
Conditions
Uterine Fibroids, Heavy Menstrual Bleeding
Interventions
Elagolix, Placebo for Estradiol/Norethindrone Acetate, Estradiol/Norethindrone Acetate, Placebo for Elagolix
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
92
States / cities
Birmingham, Alabama • Mobile, Alabama • Costa Mesa, California + 79 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2020 · Synced Jul 22, 2026, 2:26 PM EDT
Withdrawn Phase 2 Interventional

Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis

NCT02794467
View directory record Official record
Conditions
Adenomyosis
Interventions
Epelsiban, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
13
States / cities
Washington D.C., District of Columbia • West Palm Beach, Florida • Champaign, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03070951
View directory record Official record
Conditions
Uterine Fibroids, Heavy Menstrual Bleeding
Interventions
OBE2109, Placebo to match OBE2109, Placebo to match Add-back, Add-back
Drug
Lead sponsor
ObsEva SA
Industry
Eligibility
18 Years and older · Female only
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
23
States / cities
Chino, California • Huntington Park, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Jul 22, 2026, 2:26 PM EDT
Not yet recruiting Phase 4 Interventional

Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy

NCT07664956
View directory record Official record
Conditions
Minimally Invasive Surgical Procedures, Abnormal Uterine Bleeding, Unspecified, Adenomyosis of Uterus, Fibroid Uterus, Chronic Pelvic Pain, Endometriosis, Menorrhagia, Endometritis, Adnexal Diseases
Interventions
Cyclobenzaprine
Drug
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jul 22, 2026, 2:26 PM EDT